[{"id":"04d8f3c7-64bd-44c3-be44-47d8879d4d9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05832892","created_at":"2023-04-27T14:05:02.983Z","updated_at":"2024-07-02T16:34:26.014Z","phase":"Phase 1/2","brief_title":"Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer","source_id_and_acronym":"NCT05832892","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • CTLA4 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CTLA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • erfonrilimab (KN046) • Sulanda (surufatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-14"},{"id":"fd66e2fe-fd06-45f6-9687-e9f105e1a997","acronym":"","url":"https://clinicaltrials.gov/study/NCT04326257","created_at":"2021-01-18T20:57:23.420Z","updated_at":"2025-02-25T14:29:11.740Z","phase":"Phase 2","brief_title":"Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy","source_id_and_acronym":"NCT04326257","lead_sponsor":"Dan Zandberg","biomarkers":" LAG3 • CTLA4","pipe":" | ","alterations":" LAG3 expression • CTLA4 expression","tags":["LAG3 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAG3 expression • CTLA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 08/12/2023","primary_completion_date":" 08/12/2023","study_txt":" Completion: 08/12/2024","study_completion_date":" 08/12/2024","last_update_posted":"2024-02-07"},{"id":"9687712d-99d6-4383-b6f4-ea8c602d3944","acronym":"CAT_PB","url":"https://clinicaltrials.gov/study/NCT06065592","created_at":"2023-10-04T16:11:23.801Z","updated_at":"2024-07-02T16:35:34.331Z","phase":"Phase 1","brief_title":"Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms","source_id_and_acronym":"NCT06065592 - CAT_PB","lead_sponsor":"Lebanese University","biomarkers":" PD-1 • VEGFA • CDKN2B • TNFA • CTLA4","pipe":" | ","alterations":" CTLA4 expression","tags":["PD-1 • VEGFA • CDKN2B • TNFA • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTLA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 02/01/2019","start_date":" 02/01/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-06"},{"id":"48e9888e-1610-4808-9875-839623d633eb","acronym":"CP-COPD","url":"https://clinicaltrials.gov/study/NCT04654104","created_at":"2021-01-19T20:41:13.728Z","updated_at":"2024-07-02T16:36:00.909Z","phase":"","brief_title":"Immune Checkpoints in COPD","source_id_and_acronym":"NCT04654104 - CP-COPD","lead_sponsor":"University of Catanzaro","biomarkers":" PD-L1 • PD-1 • CTLA4 • HAVCR2","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression • HAVCR2 expression • CTLA4 expression","tags":["PD-L1 • PD-1 • CTLA4 • HAVCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression • HAVCR2 expression • CTLA4 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 11/20/2020","start_date":" 11/20/2020","primary_txt":" Primary completion: 11/30/2020","primary_completion_date":" 11/30/2020","study_txt":" Completion: 12/10/2023","study_completion_date":" 12/10/2023","last_update_posted":"2022-11-07"},{"id":"5c915e24-3c58-4466-86ca-c8a54189cd55","acronym":"Zirconipi","url":"https://clinicaltrials.gov/study/NCT03313323","created_at":"2021-01-18T16:21:49.240Z","updated_at":"2025-02-25T14:26:48.454Z","phase":"Phase 2","brief_title":"Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma","source_id_and_acronym":"NCT03313323 - Zirconipi","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" CTLA4 • CD4","pipe":" | ","alterations":" CTLA4 expression • CD4 expression","tags":["CTLA4 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTLA4 expression • CD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 02/16/2017","start_date":" 02/16/2017","primary_txt":" Primary completion: 02/15/2022","primary_completion_date":" 02/15/2022","study_txt":" Completion: 02/15/2022","study_completion_date":" 02/15/2022","last_update_posted":"2021-04-15"},{"id":"b4c9f83c-8626-47ee-9e52-e028530c5264","acronym":"POIR","url":"https://clinicaltrials.gov/study/NCT03549546","created_at":"2021-01-18T17:28:29.609Z","updated_at":"2024-07-02T16:36:57.640Z","phase":"","brief_title":"Expression of the Inhibitory Receptors on Lymphocytes T Cells After Lung Cancer Surgery.","source_id_and_acronym":"NCT03549546 - POIR","lead_sponsor":"Centre Hospitalier Universitaire de Saint Etienne","biomarkers":" CD8 • PD-1 • CTLA4 • HAVCR2 • CD4 • IL2","pipe":" | ","alterations":" PD-1 expression • HAVCR2 expression • CTLA4 expression","tags":["CD8 • PD-1 • CTLA4 • HAVCR2 • CD4 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression • HAVCR2 expression • CTLA4 expression"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 06/14/2018","start_date":" 06/14/2018","primary_txt":" Primary completion: 02/06/2019","primary_completion_date":" 02/06/2019","study_txt":" Completion: 02/12/2019","study_completion_date":" 02/12/2019","last_update_posted":"2019-07-26"}]